ArticleThe Laryngoscope2026
Outcomes in the Management of Pediatric Retrograde Cricopharyngeal Dysfunction.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the presentation and treatment outcomes of pediatric patients with retrograde cricopharyngeal dysfunction (RCPD).
methodsA retrospective chart review was performed on pediatric patients diagnosed with retrograde cricopharyngeal dysfunction (RCPD) and treated with cricopharyngeal botulinum toxin injection (CPBTI). Patient-specific demographic, clinical, and treatment data were collected with a focus on outcomes and complications.
resultsTwenty-five patients were identified (mean ± SD age, 14.4 ± 3.91; range 4-17). Eighteen (72%) patients were female. Common presenting symptoms included inability to belch (100%), bloating (96%), excessive flatulence (92%), and gurgling sounds from the throat (88%). Patients under 5 years of age were noted by parents to have visible abdominal distention and food aversion. Eleven patients (46%) had social anxiety related to their symptoms prior to intervention. Seven (28%) had alternate diagnoses prior to initial consultation. The average duration of follow-up was 247 days. All patients (100%) experienced symptomatic improvement, with 88% noting complete symptom resolution and 12% noting reduced symptoms. Only one patient required a second injection to maintain their treatment response.
conclusionRCPD presents similarly in both pediatric and adult patients, though the ability to verbally express symptoms may limit recognition in younger patients. Pediatric patients appear to better tolerate expected side effects of treatment and demonstrate a higher overall long-term success rate when compared to adult outcomes in the literature. Increased recognition and treatment of RCPD in children may help minimize long term sequelae of the condition while also affording decreased treatment morbidity. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.